Name: Stephen From
New title: CEO, Vicarious Surgical
Previous title: CEO, Aruna Bio
Vicarious Surgical named Stephen From as CEO, effective Aug. 7. Co-founder Adam Sachs will step down as CEO and remain on the leadership team as company president and a member of the board, according to the Thursday announcement.
From most recently was CEO of Aruna Bio, a biotech firm developing neural exosomes to treat neurodegenerative diseases. He has more than 20 years of leadership experience in the healthcare and financial industries.
Before joining Aruna, From was executive chairman of Kiora Pharmaceuticals, formerly known as EyeGate Pharmaceuticals, where he oversaw an initial public offering and multiple acquisitions and licensing transactions. Before that, From was CFO of Centelion, then a biotech subsidiary of Sanofi‑Aventis, and spent several years in investment banking, focused on the life sciences sector.
“I believe his leadership and experience are exactly what we need at this pivotal stage,” Sachs said in a statement.
In the role of president, Sachs takes over for Randy Clark, who resigned from the position in April after just over a year on the job. Clark also joined Vicarious’ board in April and, according to his LinkedIn account, is now an executive with Thermo Fisher Scientific.
On a May earnings call, Sachs said Vicarious is preparing for the first human cases with its robot and is advancing through the approval process required to perform the procedures. The company’s pivotal trial is focused on ventral hernia repair.
Vicarious previously delayed its expected de novo submission to the Food and Drug Administration until late 2026.
The company is working with UMass Memorial Medical Center, the UMass Memorial Health system’s flagship hospital, to promote adoption of its robotic surgery system.
